PMD 3112

Drug Profile

PMD 3112

Latest Information Update: 27 Dec 2007

Price : $50

At a glance

  • Originator Tularik
  • Class
  • Mechanism of Action Sodium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 12 Jul 2001 Preclinical development for Thrombosis in USA (Unknown route)
  • 20 Jul 2000 Protherics has licensed PMD 3112 to Eli Lilly in the USA
  • 14 Mar 2000 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top